InsidersTradesSigma
Follow the 셀레믹스 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 셀레믹스 has logged 25 reports. Market capitalisation: €157.1bn. The latest transaction was reported on 16 July 2026 (Purchase). Among the most active insiders: 김효기. Every trade is openly available.
21
Insider Decl.
n/a
Thresholds
€9m
6 ops.
Buy Volume
€1m
6 ops.
Sell Volume
4Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,529 of 29,063 companies
27.2
score / 100
Value28
Quality27
FCF yld-2.4%
Earn yld-2.6%
EV/EBITDA·
ROE-37%
Gross mgn50%
Net mgn-70%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 July 2026
Declarations25 total
Other
Other
Other
Other
1,021,143 shares13.83% mcapKRXDART:20260507000371
ShareKRXDART:20260507000379
25 of 25 declarations
About 셀레믹스
셀레믹스 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for the diagnosis and treatment of diseases.